In a strategic move designed to bolster its bioeconomy, China’s State Council recently approved a new pilot program in the Jiangsu Free Trade Zone (FTZ), which will be used as a testing ground for system-wide innovation in the biopharma sector. One of the core innovations of the plan is

At a meeting last week, the Senate Committee on Homeland Security and Government Affairs considered a bill that would "prohibit contracting with certain biotechnology providers," with four Chinese companies named.